Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma.

Finally, clonal diversity was increased in responders compared with nonresponders at restaging and off-study, which approached but did not reach statistical significance ( P > 0.05; Fig. 4G ).

also in 111,027 other papers

Nonetheless, throughout the manuscript, we show nominally significant results as P < 0.05 and adjusted P values represented as FDR < 0.05.

also in 7,732 other papers